Brolucizumab Protocol for Chronic Central Serous Chorioretinopathy Compared to Multivitamins
Photo by Logan Voss / Unsplash
Key Takeaway
Note that this is a protocol only; no results are available to guide clinical use of brolucizumab for chronic CSCR.
This article presents the protocol for a randomized controlled trial investigating intravitreal brolucizumab for chronic central serous chorioretinopathy (CSCR). The study plans to enroll 42 patients with chronic CSCR lasting more than 3 months and persistent intraretinal and/or subretinal fluid. Participants will be randomized to receive either intravitreal brolucizumab or oral multivitamins as a comparator.
The primary outcome is fluid resolution on optical coherence tomography (OCT) at 1 and 3 months. Secondary outcomes include best-corrected visual acuity, microperimetry, and the NEI-VFQ 25 subjective questionnaire. Follow-up is scheduled at 1 and 3 months.
Safety data, including adverse events, serious adverse events, and discontinuations, are not reported in this protocol. Limitations are not described, and funding sources or conflicts of interest are not disclosed.
As this is a protocol, no results are available. Clinicians should await trial completion and publication of results before considering brolucizumab for chronic CSCR. The use of oral multivitamins as a comparator may limit direct comparison to standard treatments.
More on Chronic Central Serous Chorioretinopathy
View Original Abstract ↓
PURPOSE: Established consensus is lacking for the management of chronic central serous chorioretinopathy (CSCR). The role of anti-VEGF agents in treating chronic CSCR in the absence of choroidal neovascular membrane (CNVM) is equivocal. We aim to study intravitreal brolucizumab in the treatment of persistent macular fluid in chronic CSCR without CNVM.
METHODS: This study is a prospective randomized, placebo-controlled trial to be conducted among 42 patients with chronic CSCR (>3 months duration) with persistent intraretinal and/or subretinal fluid. Patients will be randomized in a 1:1 ratio to receive brolucizumab or oral multivitamins. Primary endpoint will be fluid resolution on OCT at 1 and 3 months. Secondary outcome measures will include the best-corrected visual acuity, microperimetry and NEI-VFQ 25 subjective questionnaire.
CONCLUSION: The results of this study will provide an understanding of the efficacy and safety of brolucizumab in achieving fluid resolution in chronic CSCR without CNVM.
Obstructive Sleep Apnea Associated with Higher Odds of Age-Related Macular Degeneration
Large study links obstructive sleep apnea to higher risk of age-related macular degeneration
Related in Ophthalmology
Corneal biomechanics and endothelial morphology in healthy Saudi adults: a cross-sectional study
Thicker corneas in healthy adults drive lower pressure readings
This cross-sectional study of 122 healthy Saudi adults aged 18–40 years found that corneal biomechanics are primarily driven by central corn…
In a Saudi group of healthy adults, thicker corneas were the main factor lowering pressure readings, while eye shape played a smaller role.
AI-based fluid volume quantification predicts visual acuity in neovascular AMD better than CST
AI fluid measurements better predict vision loss than thickness in AMD
This randomized phase III trial in 290 eyes with neovascular AMD found that AI-based quantification of intraretinal and subretinal fluid vol…
AI-based fluid volume tracking explains more vision changes than standard thickness measurements in macular degeneration patients.
Aflibercept 8 mg extended dosing maintains visual gains with fewer injections versus 2 mg every 8 weeks in DME.
Aflibercept 8 mg every 16 weeks matches standard dosing for diabetic macular edema
This randomized, double-masked, noninferiority phase 2/3 trial enrolled 658 patients aged ≥ 18 years with center-involved diabetic macular e…
A new trial shows that aflibercept 8 mg every 16 weeks works as well as the standard 2 mg every 8 weeks for diabetic macular edema with fewe…
Motivational Interviewing Workshop Improves Communication Skills in Ophthalmology Residents
Motivational Interviewing Workshop Boosts Glaucoma Counseling Skills
This pilot RCT with 20 ophthalmology residents found that a 1-hour Motivational Interviewing workshop improved standardized patient encounte…
A simple one-hour class helps doctors talk to glaucoma patients in ways that actually change behavior and improve medication use.
From Other Specialties
Sequential SBRT, pembrolizumab, and resection in oligometastatic colorectal cancer shows 60% 1-year RFS
Phase Ib trial shows promising signs for colorectal cancer treatment
This Phase Ib clinical trial evaluated sequential stereotactic body radiotherapy, pembrolizumab, and resection in 15 patients with oligometa…
A Phase Ib trial found that a specific combination therapy helped 60% of patients stay free from cancer recurrence for one year.
Review of animal models shows unclear causal links between microbial dysbiosis and pulmonary fibrosis.
Your Gut Microbes May Shape Lung Fibrosis Treatment
This review examined animal models regarding pulmonary fibrosis. The study noted that reliance on acute-injury models inadequately represent…
Your gut microbes may influence lung scarring, opening new paths for treatment beyond current drugs.
Perspective review discusses chronic air pollution effects on children and older adults in Puerto Rico
Air pollution may change your body’s microbes and raise cancer risk
This perspective review examines the impact of chronic air pollution and environmental exposures on children and older adults. The scope inc…
Tiny particles in the air we breathe may be altering the body’s microbiome and increasing cancer risk, especially in kids and older adults l…
Total hip arthroplasty with rehabilitation improves WOMAC and HHS scores versus conservative exercise in hip osteoarthritis
Hip replacement beats exercise for severe hip arthritis
This single-centre randomized controlled trial enrolled 120 patients with moderate-to-severe hip osteoarthritis (Kellgren-Lawrence grades 2 …
A new trial finds hip replacement plus rehab dramatically outperforms exercise alone for moderate-to-severe hip osteoarthritis.